[Changes in circulating levels of calcium and bone metabolism biochemical markers in patients receiving denosumab treatment].
Denosumab can suppress BTMs and has a good therapeutic effect in patients with primary osteoporosis, but reduction of blood calcium and elevation of PTH levels can occur during the first 3 months in spite of calcium supplementation. Blood calcium and PTH levels can recover the baseline levels as the treatment extended, suggesting the importance of monitoring blood calcium and PTH levels during denosumab treatment.
Authors
- Wen Wu (ORCID: https://orcid.org/0000-0002-5576-2999)
- Ling Xu (ORCID: https://orcid.org/0009-0000-3422-7623)
- Yuancheng Chen (ORCID: https://orcid.org/0000-0002-5731-9114)
- Xueying Chen (ORCID: https://orcid.org/0000-0002-5167-3550)
- Ximei Zhi
- Haiou Deng
- Qianwen Huang (ORCID: https://orcid.org/0000-0003-4493-4721)
- Ruixue Wang (ORCID: https://orcid.org/0009-0002-5428-4574)
- Liping Xuan
Institutions
- Guangdong Academy of Medical Sciences (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-04-20
- DOI
- https://doi.org/10.12122/j.issn.1673-4254.2025.04.11
- Primary Topic
- Bone health and treatments
- Type
- article